Share-based Payment Arrangement, Expense of Immuneering Corp from 30 Jun 2020 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Immuneering Corp quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Jun 2020 to 30 Sep 2025.
  • Immuneering Corp Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $1,456,080, a 11% decline year-over-year.
  • Immuneering Corp Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $6,398,033, a 0.3% decline year-over-year.
  • Immuneering Corp annual Share-based Payment Arrangement, Expense for 2024 was $6,501,366, a 14% increase from 2023.
  • Immuneering Corp annual Share-based Payment Arrangement, Expense for 2023 was $5,727,135, a 41% increase from 2022.
  • Immuneering Corp annual Share-based Payment Arrangement, Expense for 2022 was $4,064,446, a 125% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Immuneering Corp Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $6,398,033 $1,456,080 -$184,036 -11% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $6,582,069 $1,524,943 -$136,806 -8.2% 01 Apr 2025 30 Jun 2025 10-Q 13 Aug 2025 2025 Q2
Q1 2025 $6,718,875 $1,692,267 +$217,509 +15% 01 Jan 2025 31 Mar 2025 10-Q 05 May 2025 2025 Q1
Q4 2024 $6,501,366 $1,724,743 +$84,155 +5.1% 01 Oct 2024 31 Dec 2024 10-K 20 Mar 2025 2024 FY
Q3 2024 $6,417,211 $1,640,116 +$160,956 +11% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 $5,194,506 $1,661,749 +$327,867 +25% 01 Apr 2024 30 Jun 2024 10-Q 13 Aug 2025 2025 Q2
Q2 2024 $600,000 -$733,882 -55% 21 May 2024 10-Q 12 Nov 2025 2025 Q3
Q1 2024 $5,928,388 $1,474,758 +$201,253 +16% 01 Jan 2024 31 Mar 2024 10-Q 05 May 2025 2025 Q1
Q4 2023 $5,727,135 $1,640,588 +$592,425 +57% 01 Oct 2023 31 Dec 2023 10-K 20 Mar 2025 2024 FY
Q3 2023 $5,134,710 $1,479,160 +$412,948 +39% 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2024 2024 Q3
Q2 2023 $4,721,762 $1,333,882 +$281,461 +27% 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024 2024 Q2
Q1 2023 $4,440,301 $1,273,505 +$375,855 +42% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q4 2022 $4,064,446 $1,048,163 +$415,580 +66% 01 Oct 2022 31 Dec 2022 10-K 01 Mar 2024 2023 FY
Q3 2022 $3,648,866 $1,066,212 +$429,406 +67% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $3,219,460 $1,052,421 +$701,412 +200% 01 Apr 2022 30 Jun 2022 10-Q 03 Aug 2023 2023 Q2
Q1 2022 $2,518,048 $897,650 +$715,425 +393% 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023 2023 Q1
Q4 2021 $1,802,623 $632,583 01 Oct 2021 31 Dec 2021 10-K 06 Mar 2023 2022 FY
Q3 2021 $636,806 +$326,341 +105% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $351,009 +$63,455 +22% 01 Apr 2021 30 Jun 2021 10-Q 10 Aug 2022 2022 Q2
Q1 2021 $182,225 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q1
Q3 2020 $310,465 01 Jul 2020 30 Sep 2020 10-Q 09 Nov 2021 2021 Q3
Q2 2020 $287,554 01 Apr 2020 30 Jun 2020 10-Q 09 Sep 2021 2021 Q2

Immuneering Corp Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $6,501,366 +$774,231 +14% 01 Jan 2024 31 Dec 2024 10-K 20 Mar 2025 2024 FY
2023 $5,727,135 +$1,662,689 +41% 01 Jan 2023 31 Dec 2023 10-K 20 Mar 2025 2024 FY
2022 $4,064,446 +$2,261,823 +125% 01 Jan 2022 31 Dec 2022 10-K 01 Mar 2024 2023 FY
2021 $1,802,623 +$715,854 +66% 01 Jan 2021 31 Dec 2021 10-K 06 Mar 2023 2022 FY
2020 $1,086,769 01 Jan 2020 31 Dec 2020 10-K 10 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.